Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Glycemic Control and Variability for Congestive Heart Failure Exacerbation

This study has been completed.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Kathleen Dungan, The Ohio State University Identifier:
First received: December 19, 2008
Last updated: November 9, 2013
Last verified: November 2013
High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.

Condition Intervention Phase
Congestive Heart Failure
Diabetes Mellitus
Drug: Intravenous insulin
Drug: Subcutaneous insulin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Glycemic Control and Variability for Congestive Heart Failure Exacerbation

Resource links provided by NLM:

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • Hospital Length of Stay [ Time Frame: participants were followed for the duration of hospital stay, median hospital stay 8 day ]
    Duration of hospitalization

  • Hospital Readmission [ Time Frame: 30 days ]
    All-cause hospital readmission within 30 days

Secondary Outcome Measures:
  • High Frequency Heart Rate Variability [ Time Frame: 24 hours ]
    High frequency heart rate variability (HF HRV)is a measure of cardiac autonomic tone. Electrocardiographic measures were obtained using a Bionex system (Mindware, Gahanna, OH). The electrocardiogram was performed in the standard lead II configuration. Software (Mindware, Gahanna, OH) was used to derive HF HRV. HF HRV was calculated using power spectral analysis.

  • Pre-ejection Period (PEP) [ Time Frame: 24 hours ]
    Pre-ejection period (PEP) is the time between the onset of electrical depolarization of the ventricle and the opening of the aortic valve, a measure of sympathetic tone. It is obtained noninvasively using cardiac impedance obtained using a Bionex system (Mindware, Gahanna, OH). PEP is measured in milliseconds; lower values reflect higher sympathetic tone.

  • High Sensitivity C-reactive Protein (Hs-CRP) [ Time Frame: 72 hours ]
    High sensitivity C-reactive Protein (hs-CRP) is a measure of inflammation. hsCRP (range 0-15 mg/L) was performed using Immunlite 1000 assay (Siemens; Erlangen, Germany).

  • Brain Natriuretic Peptide (BNP) [ Time Frame: 72 hours ]
    Laboratory analyses were performed by the study institution's Clinical Research Center using standard commercial kits

  • Quality of Life [ Time Frame: 30 days ]
    Quality of Life was measured using the Minnesota Living with Heart Failure Questionnaire, which is a 21 question survey that uses a likert scale of 0-5. Each item asks over the past 4 weeks whether they have had a particular symptom of heart failure and to classify the response as no symptoms (0) to having the symptom very much (5). Responses are summed for a total score (0-105).

  • Glycemic Lability Index (GLI) [ Time Frame: 24 hours ]
    GLI is a measure of glycemic variability. GLI is the sum of the square of the difference between successive glucose measurements divided by the difference in time between measurements

  • Coefficient of Variation (CV) [ Time Frame: 24 hours ]
    CV is a measure of glycemic variability

  • Mean Glucose [ Time Frame: 24 hours ]
    mean sensor glucose

Enrollment: 75
Study Start Date: January 2009
Study Completion Date: September 2013
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intravenous insulin Drug: Intravenous insulin
Patients will receive continuous insulin infusion through the vein.
Active Comparator: Subcutaneous Insulin
4 injections of insulin/day
Drug: Subcutaneous insulin
4 injections of insulin/day

Detailed Description:
High glucose as well as fluctuations in blood glucose can contribute to severe hospital complications and even death. Studies also suggest that heart failure patients who have high glucose or diabetes do not live as long as patients with normal glucose. Glucose fluctuations have not been well-studied in patients with heart failure. In this study, we will determine whether better control of blood sugar fluctuations in the hospital improve outcomes. We will enroll 80 patients with severe heart failure and divide them into 2 groups. We will use intravenous (given through the vein) insulin to lower blood sugar levels in group 1, and insulin injections (under the skin) in group 2. We will determine whether intravenous insulin improves blood markers of inflammation, changes in vital signs, and other tests that predict mortality in patients with heart failure.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 and above
  • Admitted (less than 48 hours) to the with worsening heart failure
  • Hyperglycemia or diabetes. Hyperglycemia is defined as blood glucose greater than 150 mg/dL on at least 2 occasions separated by at least 4 hours apart, insulin use, or HbA1c >6.5%.

Exclusion Criteria:

  • Type 1 diabetes
  • Receiving comfort care measures only
  • Hospital stay expected to be less than 2 days
  • Pregnancy
  • Prisoners
  • Participation in the study on prior hospitalizations
  • Acute myocardial infarction within 3 months
  • End stage renal or liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00812487

United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Kathleen Dungan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Kathleen M Dungan, MD Ohio State University
  More Information

Responsible Party: Kathleen Dungan, Assistant Professor, The Ohio State University Identifier: NCT00812487     History of Changes
Other Study ID Numbers: 2008H0087
1R21DK081877-01 ( US NIH Grant/Contract Award Number )
Study First Received: December 19, 2008
Results First Received: September 6, 2013
Last Updated: November 9, 2013

Keywords provided by Ohio State University:
congestive heart failure
diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Failure
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 22, 2017